Last reviewed · How we verify

Hemoporfin PDT

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · FDA-approved active Small molecule

Hemoporfin is a photosensitizer that generates reactive oxygen species upon light activation to destroy tumor cells in photodynamic therapy.

Hemoporfin is a photosensitizer that generates reactive oxygen species upon light activation to destroy tumor cells in photodynamic therapy. Used for Esophageal cancer, Gastric cancer, Bladder cancer.

At a glance

Generic nameHemoporfin PDT
SponsorShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Drug classPhotosensitizer
TargetPorphyrin-based photosensitizer (non-receptor mediated)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Hemoporfin is a hematoporphyrin derivative that accumulates in tumor tissue. When activated by red light at specific wavelengths, it undergoes photochemical reactions that produce singlet oxygen and free radicals, causing direct tumor cell death and vascular damage. This mechanism enables selective destruction of malignant tissue while minimizing damage to surrounding healthy tissue.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results